Genmab Announces Financial Results for the First Quarter of 2024
2/5 17:02
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcoritamab-bysp) for the treatment of adult...